Generic Topicort Availability

Topicort is a brand name of desoximetasone topical, approved by the FDA in the following formulation(s):

TOPICORT (desoximetasone - ointment;topical)

TOPICORT (desoximetasone - spray;topical)

  • Manufacturer: TARO
    Approval date: April 11, 2013
    Strength(s): 0.25% [RLD]

Has a generic version of Topicort been approved?

No. There is currently no therapeutically equivalent version of Topicort available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Topicort. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Composition and method for treatment of psoriasis
    Patent 5,990,100
    Issued: November 23, 1999
    Inventor(s): Rosenberg; E. William & Glenn; Thomas M. & Skinner, Jr.; Robert B. & Noah; Patricia W.
    Assignee(s): Panda Pharmaceuticals, L.L.C. The University of Tennessee Research Corporation
    Pharmaceutical compositions and methods for use in the treatment of psoriasis, having isopropyl myristate as a first active ingredient and a different anti-psoriatic agent as a second active ingredient; preferably they are combined in the same pharmaceutical composition.
    Patent expiration dates:
    • March 24, 2018
      Drug product
  • Stable liquid desoximethasone compositions with reduced oxidized impurity
    Patent 8,277,780
    Issued: October 2, 2012
    Inventor(s): Rao; Srinivasa & Dixit; Suresh & Yacobi; Avraham & Bailey; Arthur
    Assignee(s): Taro Pharmaceutical North America, Inc.
    The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C2-C4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C2-C4 alcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9α-fluoro-11β-hydroxy-16a-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.
    Patent expiration dates:
    • April 23, 2028
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 11, 2016 -


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.